The BIO-Europe Biopharma C-Suite Agenda Survey 2026 delivers a data-led perspective on how industry leaders are responding to renewed dealmaking momentum, persistent capital constraints and shifting competitive dynamics across global markets.
Based on responses from 81 senior executives—including 50 CEOs—this report captures the strategic tensions and opportunities defining biopharma today: from AI's evolving role in R&D to Europe's changing position in the global innovation landscape.
